Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.71 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL29047726 | 1.00 | SLC22A1 (0.71) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL21372576 | 0.97 | SLC22A1 (0.67) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL29241995 | 0.97 | SLC22A1 (0.67) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL16343544 | 0.97 | SLC22A1 (0.67) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL16093910 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL5786099 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL28648669 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL29046873 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrabuthylammonium SCHEMBL27862791 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 | |
| Tetrapentylammonium SCHEMBL2274102 | 0.94 | SLC22A1 (0.71) | SLC22A1SLC22A2TSHRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12615983-B2 | Methods for wet atomic layer etching of silicon dioxide | TOKYO ELECTRON LIMITED (JP) | 2026-04-28 | — | — | US | claimed |
| US-20250293039-A1 | METHODS FOR WET ATOMIC LAYER ETCHING OF SILICON DIOXIDE | TOKYO ELECTRON LIMITED (JP) | 2025-09-18 | — | — | US | claimed |
| CN-118561313-A | Method for synthesizing copper halide-based colloid nanocrystalline at room temperature and application | 浙江大学 | 2024-08-30 | — | — | CN | claimed |
| CN-116987033-A | Fluorescent probe for monitoring slight alkalization of lysosome in slightly acidic environment and preparation method and application thereof | 重庆医科大学 | 2023-11-03 | — | — | CN | claimed |
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | WASHINGTON UNIVERSITY (US) | 2023-07-25 | — | — | US | claimed |
| CN-112807276-A | Preparation method and application of pyridazinone myocardial perfusion PET radiopharmaceutical | 北京先通国际医药科技股份有限公司 | 2021-05-18 | — | — | CN | claimed |
| CN-112409282-A | Biphenyltetrazole acetone adduct and preparation method thereof | 浙江华海药业股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| US-10377756-B2 | 18F-labelled folates | Merck & Cie (CH) | 2019-08-13 | — | — | US | claimed |
| US-20180037805-A1 | Composition and Method for Making Converter-Dissolver Composition for Dissolving Metal Sulfate Scales from Surfaces | NuGeneration Technologies, LLC dba NuGenTec (US) | 2018-02-08 | — | — | US | claimed |
| WO-2018026436-A1 | COMPOSITION AND METHOD FOR MAKING CONVERTER-DISSOLVER COMPOSITION FOR DISSOLVING METAL SULFATE SCALES FROM SURFACES | NuGeneration Technologies, LLC (US) | 2018-02-08 | — | — | WO | claimed |
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1142049-B1 | HYDROFLUORIC ACID SCAVENGER | DANIONICS AS (DK) | 2002-09-18 | — | — | EP | claimed |
| WO-2000042672-A9 | HYDROFLUORIC ACID SCAVENGER | DANIONICS AS (DK) | 2001-11-15 | — | — | WO | claimed |
| EP-1142049-A2 | HYDROFLUORIC ACID SCAVENGER | DANIONICS A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2000042672-A2 | HYDROFLUORIC ACID SCAVENGER | DANIONICS A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| US-5693599-A | Flux washing agent | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-12-02 | — | — | US | claimed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | claimed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12615983-B2 | Methods for wet atomic layer etching of silicon dioxide | SIGLEC7, SIGLEC9, ASH2L | SLC22A1 2411/4885SLC22A2 2139/4885TSHR 3029/4885 |
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | STX18, PFAS, FLI1 | SLC22A1 1970/4885SLC22A2 1823/4885TSHR 9/4885 |
| US-10377756-B2 | 18F-labelled folates | FOLR1, FOLR2, SLC19A1 | SLC22A1 312/4885SLC22A2 386/4885TSHR 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.